Intellia Therapeutics Inc buy JPMorgan Chase & Co.
Start price
31.03.23
/
50%
€33.87
Target price
31.03.24
€72.55
Performance (%)
-24.45%
End price
01.04.24
€25.59
Summary
This prediction ended on 01.04.24 with a price of €25.59. The prediction for Intellia Therapeutics Inc disappointed with a performance of -24.45%. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | -1.907% | -1.907% | -9.171% | -75.948% |
| iShares Core DAX® | 2,59 % | 2,69 % | 6,41 % | 53,61 % |
| iShares Nasdaq 100 | -0,91 % | -7,37 % | 20,65 % | 72,78 % |
| iShares Nikkei 225® | 0,15 % | -10,20 % | 46,17 % | 62,43 % |
| iShares S&P 500 | -0,37 % | -0,83 % | 18,02 % | 60,74 % |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at JPMorgan Chase & Co. from $82.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten
Stopped prediction by JPMorgan_Chase___Co_ for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€19.93
12.08.24
12.08.24
€50.28
12.08.25
12.08.25
-53.83%
13.08.25
13.08.25
